FEMASYS INC. - COMMON STOCK

Femasys Announces $3.9 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

19 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Femasys’ FemaSeed Localized Directional Insemination for Infertility Receives Product Approval in Canada

18 Apr 2023 07:00:01 By Nasdaq GlobeNewswire

Femasys Inc. Announces Financial Results for the Year Ended December 31, 2022 and Provides Corporate Update

30 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Femasys Inc. to Participate in “The Post-Roe Fertility Journey” Panel Discussion at SXSW 2023

09 Mar 2023 07:00:02 By Nasdaq GlobeNewswire

Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device

19 Dec 2022 08:00:00 By Nasdaq GlobeNewswire

Femasys Inc. Reports Encouraging Promotional Launch of FemCerv at AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons

12 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

Femasys Inc. Announces Enrollment is over 25% Complete for FemaSeed® De Novo Trial Following Updated Strategic Study Design

29 Nov 2022 06:00:01 By Nasdaq GlobeNewswire

Femasys Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference

21 Nov 2022 07:30:00 By Nasdaq GlobeNewswire

Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2022 and Provides Corporate Update

10 Nov 2022 07:44:47 By Nasdaq GlobeNewswire

Femasys Inc. Provides Strategic Update on its FemaSeed® Pivotal Trial Design to Expedite Clinical Program Advancement

20 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

Femasys to Participate in 78th Annual American Society for Reproductive Medicine (ASRM) Scientific Congress

14 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

Femasys Inc. Announces the Appointment of Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs

12 Oct 2022 07:00:02 By Nasdaq GlobeNewswire

Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control

06 Oct 2022 07:01:00 By Nasdaq GlobeNewswire

Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team

29 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Femasys Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

01 Sep 2022 15:05:01 By Nasdaq GlobeNewswire

Femasys Inc. Announces Financial Results for the Second Quarter Ended June 30, 2022 and Provides Corporate Update

10 Aug 2022 15:05:01 By Nasdaq GlobeNewswire

Femasys To Participate in Upcoming BTIG Biotechnology Conference

03 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Femasys To Host Key Opinion Leader Event on FemBloc, a First-of-its-Kind Medical Solution for Permanent Birth Control and an Important Option for Women Post Overturn of Roe v. Wade

20 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

Femasys to Participate in the Women’s Health Panel Discussion Presented by Maxim Group LLC and hosted by M-Vest on Wednesday, July 13th at 11 a.m. ET

11 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Femasys Inc. Announces Existing Board Member Charles Larsen as Chairperson of the Board

06 Jul 2022 07:00:01 By Nasdaq GlobeNewswire